| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.33B | -32.1% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥0.02B | — |
| Net income | ¥0.03B | -64.6% |
| Gross margin | 37.2% | Net margin 7.7% |
| Revenue Q/Q | -32.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.21B | 62.8% |
| R&D | ¥0.07B | 20.9% |
| SG&A | ¥0.02B | 5.2% |
| Tax & other | ¥-0.01B | -1.9% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
中达安 ・ 同和药业 ・ 扬帆新材 ・ 广和通 ・ 凯普生物 ・ 德艺文创 ・ 正丹股份 ・ 透景生命 ・ 万通智控 ・ 南京聚隆 ・ 正元智慧 ・ 超频三
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies